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Abstract
Objective:  there  are  many  questions  and  little  evidence  regarding  the  diagnosis  and  treatment
of gastroesophageal  reﬂux  disease  (GERD)  in  children.  The  association  between  GERD  and  cow’sreﬂux  disease;
Gastroesophageal
reﬂux;
milk  protein  allergy  (CMPA),  overuse  of  abdominal  ultrasonography  for  the  diagnosis  of  GERD,
and  excessive  pharmacological  treatment,  especially  proton-pump  inhibitors  (PPIs)  are  some
aspects  that  need  clariﬁcation.  This  review  aimed  to  establish  the  current  scientiﬁc  evidence
for  the  diagnosis  and  treatment  of  GERD  in  children.
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Proton  pump
inhibitors;
Proton  pump
inhibitors/therapeutic
use;
Infant;
Child
Data  source:  a  search  was  conducted  in  the  MEDLINE,  PubMed,  LILACS,  SciELO,  and  Cochrane
Library electronic  databases,  using  the  following  keywords:  gastroesophageal  reﬂux;  gastroe-
sophageal  reﬂux  disease;  proton-pump  inhibitors;  and  prokinetics;  in  different  age  groups  of
the  pediatric  age  range;  up  to  May  of  2013.
Data  synthesis:  abdominal  ultrasonography  should  not  be  recommended  to  investigate  gastroe-
sophageal reﬂux  (GER).  Simultaneous  treatment  of  GERD  and  CMPA  often  results  in  unnecessary
use  of  medication  or  elimination  diet.  There  is  insufﬁcient  evidence  for  the  prescription  of
prokinetics  to  all  patients  with  GER/GERD.  There  is  little  evidence  to  support  acid  suppres-
sion  in  the  ﬁrst  year  of  life,  to  treat  nonspeciﬁc  symptoms  suggestive  of  GERD.  Conservative
treatment has  many  beneﬁts  and  with  low  cost  and  no  side-effects.
Conclusions:  there  have  been  few  randomized  controlled  trials  that  assessed  the  management
of GERD  in  children  and  no  examination  can  be  considered  the  gold  standard  for  GERD  diagnosis.
For  these  reasons,  there  are  exaggerations  in  the  diagnosis  and  treatment  of  this  disease,  which
need  to  be  corrected.
© 2013  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  
PALAVRAS-CHAVE
Doenc¸a do  reﬂuxo
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terapêutico;
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Doenc¸a  do  reﬂuxo  gastroesofágico:  exageros,  evidências  e  a  prática  clínica
Resumo
Objetivo:  há  muitas  dúvidas  e  poucas  evidências  para  o  diagnóstico  e  tratamento  da  doenc¸a do
reﬂuxo  gastroesofágico  (DRGE)  na  crianc¸a.  A  relac¸ão  entre  a  DRGE  e  a  alergia  às  proteínas  do
leite  de  vaca  (APLV),  o  uso  exagerado  da  ultrassonograﬁa  abdominal  para  diagnóstico  da  DRGE
e  o  excesso  de  medicamentos,  especialmente  dos  inibidores  de  bomba  de  prótons  (IBP),  são
alguns  aspectos  que  necessitam  esclarecimentos.  Esta  revisão  tem  como  objetivo  estabelecer
as  evidências  cientíﬁcas  atuais  para  o  diagnóstico  e  tratamento  da  DRGE  em  pediatria.
Fontes dos  dados:  foram  pesquisadas  nas  bases  de  dados  eletrônicos  do  Medline,  Pubmed,
Lilacs, Cochrane  Library  e  Scielo,  nas  diferentes  faixas  etárias  da  pediatria,  até  maio  de  2013,  as
seguintes  palavras-chave:  reﬂuxo  gastroesofágico,  doenc¸a do  reﬂuxo  gastroesofágico,  inibidores
da  bomba  de  prótons  e  procinéticos.
Síntese dos  dados:  a  ultrassonograﬁa  de  abdome  não  deve  ser  recomendada  para  pesquisa  de
reﬂuxo gastroesofágico  (RGE).  O  tratamento  simultâneo  da  DRGE  e  da  APLV  induz,  muitas
vezes,  ao  uso  desnecessário  de  medicac¸ão  ou  dieta  de  exclusão.  Não  existem  evidências  suﬁ-
cientes  para  prescric¸ão  de  procinéticos  em  todos  os  portadores  de  RGE/DRGE.  Poucas  evidências
fornecem  suporte  para  a  supressão  ácida,  no  primeiro  ano  de  vida,  para  tratamento  de  sintomas
inespecíﬁcos,  sugestivos  de  DRGE.  O  tratamento  conservador  traz  muitos  benefícios  e  poucos
gastos,  sem  efeitos  colaterais.
Conclusões: existem  poucos  estudos  controlados  e  randomizados  que  avaliam  a  DRGE  na  crianc¸a
e nenhum  exame  pode  considerado  padrão-ouro  para  o  seu  diagnóstico.  Por  esses  motivos,
ocorrem  exageros  no  diagnóstico  e  no  tratamento  dessa  doenc¸a,  e  que  necessitam  ser  corrigidos.
©  2013  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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astroesophageal  reﬂux  (GER)  is  a  condition  that  most
ommonly affects  the  esophagus,  and  is  one  of  the  most
requent complaints  in  centers  of  pediatrics  and  pediatric
astroenterology.1--3
According  to  the  latest  guidelines  from  the  North
merican Society  for  Pediatric  Gastroenterology,  Hepatol-
gy, and  Nutrition  (NASPGHAN)  and  the  European  Society
or Pediatric  Gastroenterology,  Hepatology,  and  Nutrition
ESPGHAN), published  in  2009,  GER  is  the  passage  of  the
astric contents  into  the  esophagus,  with  or  without  regur-
1itation and/or  vomiting. It  is  a  normal,  physiological
rocess, which  occurs  several  times  a  day  in  infants,  chil-
ren, adolescents,  and  adults,  when  it  causes  few  or  no
ymptoms.1 Conversely,  it  may  represent  a  pathological
a
p
sondition  named  gastroesophageal  reﬂux  disease  (GERD),
hen it  causes  symptoms  or  complications  that  are  asso-
iated with  signiﬁcant  morbidity.1,3 These  concepts  were
ecently reinforced  in  April  of  2013  by  a  new  guide-
ine that  emphasizes  important  concepts  for  the  general
ediatrician.3
The  variability  of  the  clinical  manifestations  and  out-
ome, the  lack  of  a  system  that  allows  patient  classiﬁcation,
nd the  lack  of  speciﬁc  diagnostic  tests,  result  in  confusion
egarding the  diagnosis  and  treatment  of  GER  and  GERD  in
hildren. For  this  reason,  deﬁnition  of  the  basic  concepts
uch as  GER  and  GERD,  as  well  as  understanding  regarding
he different  diagnostic  methods  and  therapeutic  options,
re of  utmost  importance  for  the  proper  guidance  of  these
atients. This  is  especially  true  because  parents  commonly
eek pediatric  care,  as  most  infants  regurgitate  in  the  ﬁrst
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TGastroesophageal  reﬂux  disease  
months  of  life,  which  does  not  mean  that  they  have  the
disease.2--4
The  diagnosis  of  GERD  is  primarily  clinical.  In  spite  of
the wide  range  of  diagnostic  tests  available,  none  is  consid-
ered as  the  gold  standard.1,3,4 In  infants  with  mild  symptoms
and no  warning  signs,  drug  therapy  is  unnecessary.  These
infants are  considered  ‘‘happy  spitters’’  and  therefore  do
not require  any  medical  treatment.  In  infants  and  young
children with  GERD  symptoms,  non-pharmacological  ther-
apy may  be  the  option  of  choice,  due  to  lack  of  drugs  with
proven efﬁcacy.3 In  older  children  and  adolescents,  in  whom
symptoms are  clearer  and  more  speciﬁc,  pharmacological
treatment is  more  often  used.1
The  objective  of  this  review  was  to  establish  the  existing
evidence in  the  scientiﬁc  literature,  in  the  light  of  current
knowledge, on  the  diagnosis  and  treatment  of  GERD.
Diagnostic tests: clinical application
Considering  that  GER  is  a  physiological  process  that  occurs
daily in  all  children,  infants,  adolescents  and  adults,  it  is  dif-
ﬁcult, in  some  situations,  to  differentiate  this  process  from
the pathological  condition,  i.e.,  GERD.1,5
Complementary  examinations  often  do  not  clarify
whether GER  is  physiological  or  pathological,  as,  to  date,
there are  no  well  established  standards  for  the  diagnosis
of GERD  through  deﬁnitive  diagnostic  methods.  Signiﬁcan-
tly, the  detection  of  reﬂux  of  gastric  contents  into  the
esophagus during  an  examination  does  not  necessarily  mean
that the  patient  has  GERD.  Therefore,  it  is  crucial  to  take
into account  the  clinical  history  and  physical  examination.
According to  the  latest  consensus,  the  clinical  history  is
enough to  conﬁrm  the  diagnosis  in  older  children  and  adoles-
cents, who  have  more  speciﬁc  GERD  symptoms.  In  infants,
symptoms are  nonspeciﬁc  (such  as  crying,  irritability,  and
refusal to  eat)  and  are  insufﬁcient  to  diagnose  or  predict
response to  therapy.1
There  is  a  group  of  pediatric  patients  that  has  a  higher
risk of  GERD,  with  greater  severity,  and  chronic  disease
and its  complications.  They  are  the  neurologically  impaired,
children with  overweight  and  obesity,  patients  with  genetic
syndromes, those  with  operated  esophageal  atresia,  those
with chronic  lung  disease,  and  premature  infants.1,3
Complementary  examinations  aim  to  document  the  pres-
ence of  GER  or  its  complications;  to  establish  an  association
between GER  and  symptoms;  to  assess  treatment  effec-
tiveness; and  to  exclude  other  conditions.  As  no  diagnostic
method can  answer  all  these  questions,  it  is  essential  to
understand the  usefulness  and  limitations  of  each  of  the
diagnostic tests  for  adequate  patient  evaluation,  as  dis-
cussed below,  to  prevent  submitting  patients  to  invasive,
expensive, and  inappropriate  tests.1,5,6
Contrast radiography of the esophagus,
stomach  and duodenum
Contrast  radiography  of  the  esophagus,  stomach  and  duo-
denum is  a  low-cost,  easy-to-perform  examination,  but  it  is
not appropriate  for  diagnosis  of  GERD.1 It  evaluates  only  the
immediate postprandial  GER,  and  it  is  unable  to  quantify  the
reﬂux episodes.2 Therefore,  its  routine  use  for  the  diagnosis
p
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f  GERD1,4 is  not  justiﬁed.  Its  main  role  is  the  anatomical
valuation of  the  upper  digestive  tract,4 and  should  be  indi-
ated in  selected  patients.
astroesophageal  scintigraphy
s  with  the  radiological  evaluation,  gastroesophageal
cintigraphy  assesses  only  the  immediate  postprandial  GER.
ts advantages  include  the  identiﬁcation  of  GER  even  after
 diet  with  neutral  pH,  gastric  emptying  evaluation,  and
etection of  pulmonary  aspiration.4 However,  the  detection
f slow  gastric  emptying  does  not  conﬁrm  GERD  diagnosis
nd should  be  studied  only  in  patients  with  clinical  mani-
estations of  gastric  retention.  Additionally,  a  normal  test
esult does  not  exclude  the  possibility  of  pulmonary  aspi-
ation. Thus,  this  test  should  not  be  required  for  routine
valuation of  GERD  in  infants  and  children.1,4
sophagogastric  ultrasound
sophagogastric  ultrasound  (US)  is  not  recommended  for
outine clinical  evaluation  of  GERD  in  infants  and  older  chil-
ren, according  to  the  recommendations  of  the  consensus.1
hen  the  results  of  the  esophagogastric  US  are  compared
ith those  of  the  24-hour  esophageal  pH-metry,  the  sensitiv-
ty is  95%,  but  the  speciﬁcity  is  only  11%  for  the  diagnosis  of
ERD, with  no  correlation  between  the  frequency  of  reﬂux
etected by  color  Doppler  US  and  the  reﬂux  index  detected
y pH-metry.7 Esophagogastric  US  plays  an  important  role
n the  differential  diagnosis  of  hypertrophic  pyloric  steno-
is, as  the  latter  can  be  diagnosed  through  ultrasonographic
valuation.1
Recently,  Savino  et  al8 published  an  article  on  the  use
f US  for  the  diagnosis  of  GERD  in  pediatrics.  This  study
stablished that  the  purposes  of  this  examination  in  the
valuation of  GERD  are:  to  evaluate  other  causes  of  symp-
oms such  as  vomiting,  apart  from  GERD;  and  to  measure  the
bdominal esophageal  length,  the  esophageal  diameter  and
all thickness,  and  the  angle  of  His,  providing  functional
nd anatomical  data.8 However,  the  authors  emphasize  the
eed to  deﬁne  diagnostic  criteria,  the  standardization  of
ests, and  reported  measures.8
What  is  currently  observed  in  clinical  practice  is  that  the
sophagogastric US  provides  information  on  the  presence
nd number  of  GER  episodes  during  the  examination.  This
nformation adds  nothing  to  the  investigation,  because  the
eﬂux may  be  physiological,  i.e.,  on  a  full  stomach  and  in
he supine  position  after  the  child  has  been  fed.  Therefore,
he US,  as  it  has  been  used,  does  not  differentiate  GER  from
ERD and  is  not  helpful  to  the  pediatrician  and  gastroen-
erologist diagnostic  approach.  Thus,  at  the  moment,  there
s no  place  for  US  as  a  routine  diagnostic  test  for  GERD  in
ediatric patients.1,5
sophageal  pH-monitoring
he  major  advantages  of  pH-monitoring  are:  to  evaluate  the
atient under  more  physiological  conditions  and  for  longer
eriods, to  quantify  GER,  and  to  correlate  episodes  of  reﬂux
ith signs  and  symptoms.9 Its  main  limitation  is  the  incapac-
ty to  detect  non-acid  or  weakly  acidic  reﬂux  episodes.1,10,11
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hus,  especially  in  infants  who  are  predominantly  or  exclu-
ively fed  wit  milk,  postprandial  GER  may  not  be  detected,
ue to  the  neutralization  of  acid  reﬂux  by  milk.
According  to  the  previous  guidelines  of  the  North  Ameri-
an Society  of  Pediatric  Gastroenterology,  pH-metry  should
e performed  only  in  situations  that  would  provide  changes
n patient  diagnosis,  treatment,  or  prognosis.9 In  this  con-
ext, the  main  indications  for  GER  assessment  by  pH-metry
emain: evaluation  of  extra-digestive  or  atypical  symptoms
f GERD;  detection  of  occult  GER;  evaluation  of  response
o clinical  treatment  in  patients  with  Barrett’s  esophagus  or
ERD that  is  difﬁcult  to  control;  and  pre-  and  postoperative
ssessment of  the  patient  with  GERD.4,9,11
When  symptoms  are  typical  or  when  GERD  has  been
iagnosed by  other  methods  such  as  upper  endoscopy,  pH-
onitoring is  not  indicated.  pH-metry  represents  a  valid
uantitative measure  of  esophageal  acid  exposure,  with
ell-established reference  values.1,3 However,  the  severity
f acid  reﬂux  is  not  consistently  correlated  with  symptom
everity or  with  demonstrable  complications.1
sophageal  intraluminal  impedance
his  is  a  new  method  that  detects  the  retrograde  movement
f ﬂuids,  solids,  and  air  in  the  esophagus,  to  any  level  and  at
ny amount,  regardless  of  pH,  that  is,  regardless  of  chemical
r physical  characteristics,  as  it  measures  changes  in  elec-
rical resistance  and  is  performed  with  multiple  channels.
herefore, this  new  technique  may  have  greater  value  than
H-metry to  monitor  the  quantity  and  quality  of  reﬂuxed
aterial.1,5,12
Currently,  it  is  always  used  in  association  with  pH
onitoring (pH-multichannel  intraluminal  impedance  --  pH-
II).12,13 pH-MII  is  superior  to  pH  monitoring  alone  to  assess
he temporal  association  between  symptoms  and  GER.1 The
wo techniques  used  together  provide  useful  measures,  but
hey  are  yet  to  be  well  determined.1
sophageal  manometry
sophageal  manometry  assesses  the  motility  of  the  esoph-
gus and  is  indicated  in  those  patients  with  symptoms
uggestive of  esophageal  dysmotility,  whose  main  symptoms
re dysphagia  and  odynophagia.1 It  may  be  useful  in  patients
ho have  not  responded  to  acid  suppression  and  have  a
egative endoscopic  ﬁndings  in  order  to  detect  motor  abnor-
alities such  as  achalasia  the  may  mimic  GERD.1 It  can  also
e used  to  locate  the  lower  esophageal  sphincter  (LES)  in
he pH-metry.
pper  gastrointestinal  endoscopy  with  biopsy
pper  gastrointestinal  endoscopy  allows  direct  visual  exam-
nation of  the  esophageal  mucosa  and  collection  of  samples
or histophatological  analysis.1,3 Thus,  it  is  useful  for  the
iagnosis of  esophageal  complications  of  GERD  (esophagitis,
eptic stricture,  or  Barrett’s  esophagus),  which  is  impor-
ant for  the  implementation  of  appropriate  therapy  and  for
atient prognosis.1--3,5 It  also  has  a  key  role  in  the  differ-
ntial diagnosis  with  other  peptic  and  nonpeptic  diseases,
m
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uch  as  eosinophilic  esophagitis  (EoE),  fungal  esophagitis,
uodenal ulcer,  gastritis  by  H.  pylori,  eosinophilic  gastroen-
eropathy, malformations,  and  cancer,  which  can  produce
ymptoms similar  to  GERD.1
Currently,  reﬂux  esophagitis  is  deﬁned  as  the  presence
f mucosal  lesions  visible  on  endoscopy,  in  the  esopha-
us, or  immediately  above  the  esophagogastric  junction.1
sophageal  mucosa  erythema  and  irregular  Z  line  are  not
ensitive enough  to  diagnose  reﬂux  esophagitis.  Similarly,
he histological  ﬁndings  of  mild  eosinophilia,  elongated
apillae, basal  layer  hyperplasia,  and  dilation  of  intercel-
ular spaces  (spongiosis)  are  not  adequate  to  make  the
iagnosis of  reﬂux  esophagitis.1 They  only  constitute  non-
peciﬁc, reactive  changes,  which  may  be  found  in  other
ypes of  esophagitis  or  even  in  normal  subjects.1 Although
he histological  assessment  of  reﬂux  esophagitis  is  not  as
mportant, endoscopic  biopsies  are  essential  in  this  group  of
atients for  the  differential  diagnosis  with  other  diseases,
uch as  EoE.
It should  also  be  considered  that  the  absence  of  esophagi-
is on  endoscopy  does  not  exclude  GERD,  as  some  patients
ave endoscopy-negative  reﬂux  disease  (non-erosive  reﬂux
isease [NERD]).
mpirical  therapeutic  test  with  acid  suppression
lder  children  and  adolescents  with  typical  symptoms  of
ERD, without  warning  signs,  can  be  submitted  to  an  empir-
cal therapeutic  trial  with  proton  pump  inhibitors  (PPIs)  for
our weeks,  which  can  be  extended  to  12  weeks  if  there
s clinical  improvement.1 Typical  symptoms  are  heartburn,
urning epigastric  pain,  chronic  cough,  especially  related
o food,  nausea  and  regurgitation,  chest  pain,  and  dyspep-
ia. However,  symptomatic  improvement  does  not  prove  the
resence of  GERD,  as  symptoms  may  respond  to  placebo  or
mprove spontaneously.  The  time  of  response  is  also  con-
roversial and  varies  from  patient  to  patient.  The  warning
igns that  should  be  investigated  are  bleeding,  weight  loss,
hronic anemia,  asthenia,  and  prostration.  There  is  no  evi-
ence to  indicate  a  therapeutic  test  in  younger  children,  in
hom symptoms  are  less  speciﬁc.1
ERD and cow’s milk protein allergy
ERD  and  cow’s  milk  protein  allergy  (CMPA)  are  common
onditions in  pediatric  patients,  especially  infants.14 There
s currently  a  large  number  of  infants  who  are  treated  con-
omitantly for  GERD  and  CMPA.  There  is  a  subgroup  of
atients, in  general,  younger  than  6  months,  who  have  CMPA
hat manifest  as  vomiting  and  regurgitation,  indistinguish-
ble from  GERD.  In  these  infants,  the  elimination  of  cow’s
ilk from  the  infant’s  or  the  mother’s  diet  may  improve  vom-
ting substantially,  and  symptoms  may  recur  when  milk  is
eintroduced in  the  diet.1
The  two  conditions  are  difﬁcult  to  diagnose,  as  there  is  a
ack of  a  validated  diagnostic  test  and  they  may  be  confused
ith many  other  conditions,  from  hunger  to  problems  in  the
other-infant relationship,  physiological  reﬂux,  and  adap-
ive  problems  of  the  digestive  system,  especially  in  infants
hose symptoms  are  nonspeciﬁc,  such  as  crying,  irritability,
nd difﬁcult  sleeping.  The  simultaneous  treatment  of  both
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conditions  often  causes  exaggerations,  frequently  resulting
in unnecessary  pharmacological  treatment  or  elimination
diet.
Several studies  support  the  hypothesis  that  there  is  a
causal relationship  between  the  two  conditions,  suggest-
ing that  there  is  a  subgroup  of  infants  in  whom  GERD
is attributable  to  CMPA.14--19 The  debate  is  the  logical
consequence of  the  fact  that  the  two  conditions  require
diagnostic examinations.14 Therefore,  the  consensus  of  the
NASPGHAN/ESPGHAN1 on  GERD  advises  a  therapeutic  trial  of
two to  four  weeks  with  an  extensively  hydrolyzed  or  amino
acid formula,  and  for  infants  who  are  breastfed,  with  a
maternal strict  CMP  elimination  diet.1 In  these  cases,  the
possibility of  GERD  caused  by  CMPA  would  be  excluded  with-
out using  unnecessary  medications.  Conversely,  the  recent
consensus on  the  diagnosis  and  treatment  of  food  allergy
of ESPGHAN  states  there  are  insufﬁcient  data  to  support
the concept  that  gastroesophageal  reﬂux  may  be  the  only
manifestation of  CMPA  in  breast-fed  infants.20 This  consen-
sus statement,  however,  cites  vomiting  and  regurgitation  as
possible symptoms  of  CMPA,  and  recommends  elimination
diet for  the  mother.20
Although  it  has  been  estimated  that  the  prevalence  of
GERD attributable  to  CMPA  is  as  high  as  56%,  this  asso-
ciation is  not  scientiﬁcally  proven.14--17 There  are  several
uncontrolled studies,  with  very  different  methodologies,
aimed at  clarifying  the  relationship  between  GERD  and  CMPA
(Table 1).18,19 However,  to  date,  this  association  remains
unclear and  there  are  still  many  points  to  be  clariﬁed.
Recently,  Borrelli  et  al.15 evaluated  a  group  of  infants
with CMPA  and  suspected  GERD  (17  children,  mean  age  of
14 months),  through  48-hour  pH-impedance  testing  with
multiple channels.  In  the  ﬁrst  24  hours,  they  were  treated
with CMP  elimination  diet  (amino  acid  formula,  which  they
had already  been  receiving  to  treat  CMPA);  in  the  subse-
quent 24  hours,  a  challenge  test  with  cow’s  milk  (cow’s
milk formula,  with  osmolarity  and  components  other  than
the protein,  similar  to  amino  acid  formula)  was  performed.
These authors  reported  that  in  infants  with  CMPA  and  sus-
pected GERD,  exposure  to  cow’s  milk  increased  the  number
of weakly  acidic  reﬂux  episodes,  identifying  a  subgroup  of
patients with  allergen-induced  GER.15 Thus,  they  recom-
mend pH-impedance  testing  as  a  diagnostic  test  for  some
cases of  infants  with  GERD  and  CMPA.15 These  data  are  not
fully corroborated  and  should  be  interpreted  with  caution.
The  mechanisms  by  which  CMPA  induces  GER  are  still
poorly understood.15 Data  from  animal  models  show  neu-
ral abnormalities  in  gastrointestinal  motility  secondary  to
immediate hypersensitivity  reactions,  inducing  delayed  gas-
tric emptying  and  changes  in  gastric  acid  secretion21 Other
studies have  shown  changes  in  gastric  myoelectric  activity
in atopic  patients,  when  exposed  to  cow’s  milk.22,23 These
changes would  occur  by  activation  and  degranulation  of
mast cells  and  eosinophils,  causing  the  release  of  cytokines
and activation  of  receptors  in  nerve  ﬁbers  of  the  digestive
tract mucosa,  which  would  result  in  contractile  and  motil-
ity abnormalities,  triggering  reﬂux  episodes  secondary  to
exposure to  the  antigen.14,15,21--23Emerenziani  and  Sifrim,24 evaluating  gastric  emptying
and pH-impedance  testing  of  some  patients,  observed  that
the slower  the  gastric  emptying,  the  higher  the  pH  and
proximal extension  of  reﬂux  episodes.  It  is  well  established
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hat  non-acidic  reﬂux  episodes  occur  during  feeding  and  in
he ﬁrst  hours  of  the  postprandial  periods.15,23 Therefore,
orrelli et  al.15 speculate  that  neuroimmune  interactions,
nduced during  the  challenge  test  with  cow’s  milk,  sup-
ress gastric  acid  production  and  alter  the  motor  activity
f the  stomach,  which  slows  gastric  emptying  and  increases
ransient relaxation  of  the  lower  esophageal  sphincter,
esulting in  an  increase  in  the  number  of  weakly  acidic  reﬂux
pisodes. This  could  explain  how  CMPA  causes  GERD,  but  it
s yet  to  be  proven.
Nevertheless,  as  these  tests  are  still  expensive  and  not
idely available,  in  addition  to  being  invasive  for  small
nfants, probably  the  most  practical  test  in  routine  prac-
ice when  there  is  doubt  is  a  trial  of  CMP-elimination  diet
or two  to  four  weeks  in  infants  with  GERD  in  whom  CMPA  is
uspected.
The variety  and  availability  of  different  formulas  is
nother important  issue  in  this  discussion.  The  addition
f nucleotides,  long  chain  polyunsaturated  fatty  acids  (LC-
UFAS), pre-  and  probiotics  may  improve  immunity  and
ecrease the  incidence  of  gastrointestinal  disorders  includ-
ng food  allergies  and  motility  disorders  such  as  GERD  and
onstipation. If  the  theoretical  beneﬁt  proclaimed  by  phar-
aceutical companies  is  real,  it  should  result  in  clinical
eneﬁt, reducing  the  prevalence  of  these  frequent  gastroin-
estinal complaints;  however,  further  studies  are  necessary
o substantiate  these  effects,14 and  the  ESPGHAN  and  the
merican Academy  of  Pediatrics  consensus  state  that  there
s not  enough  scientiﬁc  support  to  routinely  employ  these
dditives in  infant  formulas.25
The  studies  that  discuss  the  possible  association  between
ERD and  CMPA  are  shown  in  Table  1.15,17--19,22,26--31
ERD treatment
he  main  objectives  of  therapy  are  to  promote  adequate
rowth and  weight  gain,  symptom  relief,  healing  of  tissue
njuries, and  to  prevent  recurrence  and  complications  asso-
iated with  GERD.
Firstly, it  is  important  to  differentiate  between  physio-
ogical GER  and  GERD.  In  infants,  GERD  resolution  occurs,
n most  cases,  as  the  child  grows  and  develops.  Sponta-
eous resolution  is  common  and  the  course  is  generally
enign, with  low  incidence  of  complications.  Thus,  in  this
roup, clinical  treatment  with  anti-GERD  measures,  changes
n diet  and,  less  often,  pharmacotherapy  result  in  clini-
al resolution.  A small  percentage  of  young  infants  develop
ore severe  pulmonary  manifestations  due  to  aspiration,
yanosis, and  swallowing  disorders,  especially  premature
nfants and  those  with  cerebral  palsy.  Differently,  in  older
hildren, as  well  as  in  adults,  GERD  has  often  a  chronic  and
elapsing course,  and  may  lead  to  complications.  There  may
lso  be  spontaneous  resolution  in  this  group.3,6
The  decision  to  treat  GERD  is  inﬂuenced  by  the  proba-
ility of  avoiding  negative  consequences  for  the  child.  The
reatment should  be  implemented  progressively,  starting
ith general  measures  and  changes  in  lifestyle,  through  drug
herapies, and  often  ending  in  endoscopic  or  surgical  tech-
iques, which  are  more  invasive.6 It  is  always  essential  in
he initial  consultation  to  explain  to  the  parents  why  GER
nd GERD  occur,  reassuring  and  properly  advising  them,  and
110  Ferreira  CT  et  al.
Table  1  Studies  of  the  association  between  GERD  and  CMPA.
Author/country  Method  Results  Observations
Cavataio  F  et  al.18
Cavataio  F  et  al.19
Italy
pH-monitoring  to  differentiate
primary GERD  and  GERD
secondary to  CMPA
Suggests  that  a  speciﬁc  phasic  pH
pattern  occurs  in  CMPA  -  slow  and
progressive  decrease  in  pH  after
challenge  test  with  milk
Other  studies  did  not
reproduce these  ﬁndings
Ravelli AM  et  al.22
Italy
Electrogastrography  and
electrical impedance
tomography  to  study  infants
with GERD  and  CMPA
Signiﬁcant  difference  between  the
parameters  of  infants  with  GERD
(equal  to  controls)  and  with  CMPA
(gastric dysrhythmia  and  delayed
gastric  emptying)
Patients  with  CMPA  have
motility disorders  that  induce
GERD.
This study  separated  the
patients into  two  groups  and
assessed  the  differences  (GERD
x  CMPA)
Garzi  A  et  al.26
Italy
Ultrasonography  to  study
gastric emptying  in  infants
with GERD  and  CMPA  -  and  ten
normal  controls-with  formula
and protein  hydrolyzate
Improvement  in  gastric  emptying
with hydrolyzed  formula  in
patients  with  GERD  and  CMPA
All  patients  with  GERD  and
CMPA had  delayed  gastric
emptying
Nielsen et  al.17 48-hour  pH-metry  and
endoscopy
Day 1-  elimination  diet
Day 2  --  challenge  test
No difference  in  the  parameters
of reﬂux  in  pH-monitoring,  but
observed  an  association  between
GERD and  CMPA
Incapacity  of  pH-monitoring  to
detect episodes  of  non-acid
reﬂux, particularly  in  infants
who are  often  breastfed
Nielsen et  al.27 Analysis  of  UGIT  biopsies  to
verify  whether  there  was  a
different  inﬂammatory  pattern
in patients  with  GERD
secondary to  CMPA
Histology  did  not  identify  the
group  with  GERD  by  CMPA
Older children  with  a  mean  age
of 7.8  years
Semeniuk  J  et  al.28
Poland
Esophageal  manometry  in
patients with  primary  GERD
and GERD  secondary  to  CMPA
There were  no  differences
between the  two  groups
Semeniuk J  et  al.29
Poland
Endoscopy  in  patients  with
primary GERD  (group  1)  and
secondary to  CMPA  (group  2)
Esophagitis of  varying  degrees  in
33%  of  group  1  and  in  47%  of  group
2
Semeniuk  J  et  al.30
Poland
Measurement  of  serum  gastrin
in GERD  and  GERD  associated
with CMPA
Serum  concentrations  were  similar
in primary  and  secondary  GERD
Farahmand F  et  al.31 Patients  with  GERD  received
omeprazole. Non-responders
underwent an  elimination  diet.
One third  of  patients  with  GERD
responded  to  elimination  diet  that
excluded  dairy  products
Clinical study
Borrelli O  et  al.15
Italy/United  Kingdom
48-hour pH-metry-MII
Day 1  --  amino  acid  formula
Day 2-  challenge  with  cow’s
milk
The number  of  reﬂux  episodes  and
weakly  acid  episodes  increased  in
the  challenge,
They  concluded  that
pH-monitoring did  not  appear
in previous  studies,  as  what
most often  occurs  are
postprandial weakly  acidic
reﬂux episodes.
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o  closely  follow  the  evolution  of  the  patient.  Prolonged  or
epeated courses  of  drug  treatment  should  not  be  prescribed
rior to  diagnostic  conﬁrmation.1
onservative  treatment  (non-pharmacological)
ecommendations  offered  to  the  parents  and  support  to  the
amily are  essential  measures,  especially  in  small  infants
ho vomit  and  present  adequate  growth.1 The  lifestyle
hanges recommended  to  all  pediatric  patients  with  GER
nd GERD,  regardless  of  severity,  include:  not  wearing  tight
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mse; UGIT, upper gastrointestinal tract.
lothes;  diaper  changes  before  breastfeeding,  to  avoid  using
rugs  that  exacerbate  GER;  slow  infusions  in  children  with
asogastric tubes;  and  to  avoid  smoking  (active  or  pas-
ive), as  tobacco  exposure  induces  LES  relaxation,  increases
ates of  asthma,  pneumonia,  apnea,  and  sudden  infant
eath syndrome;  in  addition  to  anti-GER  dietary  and  position
uidelines,4 discussed  in  detail  below.ietetic recommendations
dolescents  should  avoid  high-volume  and  high-calorie
eals. Fatty  foods  are  not  recommended,  as  they  may  slow
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gastric  emptying  and  reduce  LES  pressure.1,4 Some  foods
such as  chocolate,  soft  drinks,  tea,  and  coffee  are  not  advis-
able. A  simple  and  uncontroversial  measure  is  to  refrain  from
eating a  few  hours  before  bedtime,  unless  there  is  signiﬁcant
malnutrition. There  is  no  evidence  to  support  the  routine
elimination of  certain  foods  for  the  treatment  of  GERD  in
older children,1 such  as  acidic  fruit.  The  recommendation  of
smaller, more  frequent  meals  is  based  on  the  likely  correla-
tion between  gastric  volume  and  the  reﬂux  index.  However,
this habit  increases  the  frequency  of  postprandial  periods,
which are  associated  with  greater  number  of  weakly  acidic
or non-acid  GER  episodes.15
pH-monitoring  and  gastroesophageal  scintigraphy  studies
have demonstrated  that  thickened  feeds  are  not  effective
anti-GER measures,  although  they  may  decrease  the  vol-
ume and  frequency  of  regurgitation  and  vomiting.1 While  it
reduces crying  and  increases  caloric  intake,  excessive  calo-
rie intake  is  a  potential  problem  of  a  thickened  diet.1,3 Its
therapeutic effect  has  not  been  determined  in  patients  with
GER that  do  not  present  vomiting  or  regurgitation.3 Anti-
regurgitation formulas  may  reduce  visible  regurgitation,  but
do  not  result  in  measurable  decrease  in  the  frequency  of
reﬂux episodes.1 A  meta-analysis  has  demonstrated  that,  in
healthy children,  thickened  formulas  are  only  moderately
effective in  the  treatment  of  physiological  GER.32
Position  guidelines
The  prone  position  is  proven  to  be  the  most  effective  anti-
GER position.3 However,  its  association  with  sudden  death
in infants,  as  well  as  that  of  the  lateral  decubitus  position,
has generated  much  controversy  regarding  the  best  anti-
GER position.1,3 Currently,  it  is  recommended  that  normal
infants or  patients  with  GERD  should  sleep  in  the  supine  posi-
tion, since  the  risk  of  sudden  death  is  more  important  than
the beneﬁt  brought  by  the  anti-GER  position.1,3 Elevating
the headboard  has  been  recommended,  although  not  proven
beneﬁcial in  controlled  studies.1--4 The  sitting  or  semi-sitting
positions for  infants  below  one  year  were  also  not  shown  to
be an  effective  anti-GER  position,  due  to  the  muscle  tonus
of infants.33
For  adolescents  and  adults,  it  is  likely  that  the  best
position is  the  left  lateral  decubitus  position,  with  the  head-
board elevated.1,3
Pharmacological  treatment
In  general,  physiological  GER  should  not  be  treated  with
medication, except  for  cases  where  the  presence  of  GERD  is
evident. Pharmacological  treatment  is  directed  primarily  to
acid suppression.  PPIs  and  H2 receptor  antagonists  effec-
tively increase  gastric  pH  and  prevent  acid  reﬂux,  which
is harmful  to  the  esophageal  mucosa.  However,  currently,
weakly or  non-acid  reﬂux  are  known  to  be  frequent  and  to
cause symptoms.14,15
There  is  no  algorithm  for  the  treatment  of  GERD  in  chil-
dren that  does  not  provokes  discussion  and  controversy  but
the recommended  drugs  are:• Contact  antacids,  recommended  only  as  symptomatic
drugs for  sporadic  symptoms  or  to  decrease  nocturnal
acidity.1
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 Prokinetics,  which  help  to  control  symptoms,  mainly  vom-
iting  and  regurgitation.
 Medications  that  reduce  acid  secretion  (histamine  H2-
receptor  antagonists  or  PPIs),  when  symptoms  such  as
retrosternal  pain  and  heartburn,  and/or  complications,
such  as  esophagitis,  are  associated  with  the  presence  of
the  acid  in  the  esophagus  or  in  other  organs,  such  as  res-
piratory  tract.
rokinetic  agents
he  use  of  prokinetics  is  based  on  the  fact  that  they  increase
ES tonus  and  improve  esophageal  clearance  and  gastric
mptying. However,  none  of  these  medications  was  shown
o be  effective  in  decreasing  the  frequency  of  transient
elaxation of  the  LES,  the  main  physiopathological  mech-
nism of  GER.  They  are  not  effective  in  inducing  healing
f esophageal  lesions  and  do  not  have  a  proven  anti-GER
ffect, rather  an  anti-regurgitation  effect.  Thus,  the  proki-
etic medications  are  often  used  in  children  who  have  a
redominance of  symptoms  of  motility  abnormalities  and
ho have  more  regurgitation  than  pain.
Currently,  there  is  insufﬁcient  evidence  for  the  rou-
ine use  of  prokinetics.1 Furthermore,  the  potential  side
ffects of  these  drugs  are  more  important  than  the  beneﬁts
chieved by  their  use  in  the  treatment  of  GERD.1
In  daily  practice,  the  use  of  prokinetics  is  always  associ-
ted with  antacids  in  the  treatment  of  GERD.  Based  on  these
oncepts, each  medication  has  its  precise  indications,  and
here is  no  need  and  no  plausible  explanation  to  justify  the
ndiscriminate use  of  two  medications  (prokinetics  and  acid
ecretion inhibitors)  at  the  beginning  of  treatment.
etoclopramide
etoclopramide  improves  gastric  emptying  and  esophageal
eristalsis, and  increases  the  pressure  in  the  LES,  but  the
arrow margin  between  therapeutic  and  adverse  effects  on
he CNS  hinders  its  use  in  children  with  GERD.  A  meta-
nalysis of  seven  controlled  studies  showed  that,  in  children
ged 1  month  to  2  years,  metoclopramide  reduces  the  daily
ymptoms of  GER  and  GER  index  in  pH-monitoring,  but
ith signiﬁcant  adverse  effects.33 The  adverse  effects  of
etoclopramide in  infants  and  children  include  lethargy,
rritability, gynecomastia,  galactorrhea,  and  extrapyrami-
al reactions,  which  have  been  reported  in  11%  to  34%  of
atients.3,33
romopride
here  are  no  controlled  trials  to  support  its  use  or  prove  its
eneﬁts. As  bromopride  has  neurological  side  effects,  such
s extrapyramidal  changes,  it  must  not  be  indicated  for  the
reatment of  GERD.34 Bromopride  is  not  mentioned  in  any  of
he pediatric  guidelines.1,3omperidone
omperidone  is  a  prokinetic  agent  that  increases  the  pres-
ure in  the  LES  and  improves  motility,  but  its  use  is  limited  in
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ediatrics  given  the  lack  of  studies  that  have  demonstrated
ts effectiveness.  A  recent  systematic  review  of  studies  with
omperidone identiﬁed  only  four  controlled  studies  in  pedi-
tric patients,  none  of  which  showed  any  robust  evidence  of
fﬁcacy in  pediatric  GERD.1,3,35
Domperidone  also  causes  occasional  extrapyramidal  side
ffects.1,35 One  of  the  major  side  effects  is  increased
rritability and  colic  in  infants,  which  often  worsens
he clinical  picture  or  further  confuses  the  pediatrician.
he simple  action  of  stopping  the  use  of  domperi-
one in  infants  who  are  experiencing  side  effects
f the  medication  can  greatly  improve  patient  symp-
oms. More  recently,  the  occurrence  of  cardiovascular
vents associated  with  the  use  of  domperidone,  includ-
ng QT  prolongation  and  ventricular  arrhythmia,  has  been
emonstrated.36,37
cid secretion inhibitors
istamine  H2-receptor  antagonists
istamine  H2-receptor  antagonists  are  drugs  that  reduce
astric acidity  by  inhibiting  the  histamine  H2 receptors
n gastric  parietal  cells.  A  dose  of  5  mg/kg  of  ranitidine
ncreases the  gastric  pH  for  9  to  10  hours  in  infants.1 Gas-
ric pH  begins  to  increase  within  30  minutes,  allowing  its
se for  fast  symptom  relief.1 Doses  of  5  mg/kg  of  raniti-
ine, every  12  hours;  or  of  3  mg/kg,  three  times  a  day,  have
een recommended  in  children.2,38 According  to  Orenstein
t al.,2 the  therapeutic  failure  of  these  medications  can
e attributed  to  the  small  doses  commonly  used  in  clinical
ractice.
Studies have  demontrated  that  H2 antagonists  (cime-
idine, ranitidine,  famotidine)  are  more  effective  than
lacebo in  relieving  GERD  symptoms  and  healing  esophageal
ucosal injury.1 The  effectiveness  of  H2 blockers  in
ealing erosive  lesions  is  much  higher  in  mild  to
oderate cases.  PPIs  are  more  effective  in  more
evere injuries,  even  when  compared  to  high  doses  of
anitidine.1
Regarding  side  effects  of  ranitidine,  some  infants  may
ave headaches,  drowsiness,  head  banging  and  other  side
ffects which,  if  interpreted  as  persistent  symptoms  of
ERD, could  result  in  an  inappropriate  increase  in  dosage.1
urthermore,  tachyphylaxis  or  decrease  in  the  response  is  a
roblem for  its  chronic  use.
As  ranitidine  has  a  liquid  formula,  it  should  be  used  when
ecessary in  infants.  If  no  satisfactory  response  is  attained,
t would  be  more  appropriate  to  evaluate  other  diagnostic
ossibilities before  prescribing  PPIs.
In  infants  with  nonspeciﬁc  symptoms  such  as  crying  and
rritability, diagnostic  tests  for  GERD  do  not  contribute  much
o the  investigation,  unless  it  is  a  severe  case  or  there
re associated  comorbidities,  such  as  neurological  disease
r operated  esophagus.  The  healthy  infant  that  does  not
espond to  conservative  measures  is  unlikely  to  have  GERD.
There  is  no  evidence  to  justify  empiric  treatment  with
cid suppression  in  infants  and  young  children,  as  GERD
ymptoms are  less  speciﬁc.1 Hence,  these  drugs  should
e indicated  when  the  diagnosis  of  reﬂux  esophagitis  is
stablished.1
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PIs
PIs  are  indicated  in  cases  of  erosive  esophagitis,  peptic
tricture, or  Barrett’s  esophagus,  as  well  as  in  children  that
eed a  more  effective  blockade  of  acid  secretion,  for  ins-
ance, in  those  with  severe  chronic  respiratory  disease  or
eurological problems.1 The  differences  between  the  PPIs
ppear to  be  very  small,  and  presentation  plays  a  critical
ole in  their  selection.
PPIs are  superior  to  H2-receptor  antagonists,  both  in
meliorating symptoms  and  healing  lesions,  and  both  are
uperior to  placebo  medication.1 In  contrast  with  H2-
lockers, the  effect  of  PPIs  does  not  decrease  with  chronic
se. It  maintains  gastric  pH  >  4  for  longer  periods,  and
nhibits acid  secretion  induced  by  feeding,  which  are  char-
cteristics not  presented  by  H2-blockers.  Its  potent  acid
uppression leads  to  a  reduction  of  intragastric  volume  for
4 hours,  which  facilitates  gastric  emptying  and  decreases
eﬂux volume.1
The  currently  available  PPIs  are  omeprazole,  pan-
oprazole, esomeprazole,  lansoprazole,  rabeprazole  and
exlansoprazole. They  may  cause  four  types  of  side
ffects in  children:  idiosyncratic  reactions,  interactions
ith other  drugs,  hypergastrinemia,  and  drug-induced
ypochlorhydria.1 The  idiosyncratic  effects  occur  in  approx-
mately 14%  of  pediatric  patients  using  PPIs:1 the  most
ommon are  headache,  diarrhea,  constipation,  and  nau-
ea, each  of  them  occurs  in  approximately  2%  to  7%  of
atients.1,3 Parietal  cell  hyperplasia  and  hyperplastic  polyps
f the  gastric  fundus  are  benign  abnormalities  caused  by
cid blocking  and  by  hypergastrinemia.1 It  should  be  consid-
red that  several  studies  have  associated  hypochlorhydria
ue to  PPIs  to  community-acquired  pneumonia,  gastroen-
eritis, candidiasis,  and  even  enterocolitis  in  preterm
nfants.1,39,40 In  adults,  they  may  cause  acute  intersti-
ial nephritis.1 Moreover,  PPIs  may  alter  the  patient’s
ntestinal microbiota  and  some  studies  suggest  that  acid
uppression may  predispose  to  the  development  of  food
llergies.1,41
PPIs  also  have  their  limitations,  as  a  consequence  of  their
harmacological properties.  They  must  be  used  before  the
rst meal,42 and  must  be  protected  from  stomach  acid  by
n enteric  coating.  A  major  problem  of  PPIs  in  Brazil  is
hat there  is  no  liquid  formulation.  Customized  liquid  for-
ulations are  not  tested  and  therefore,  their  effectiveness
s unknown.  Opening  the  pill  or  crushing  the  tablet  may
nactivate the  medication  by  removing  the  gastric  acid  pro-
ection, since  PPIs  need  to  be  intact  in  order  to  be  absorbed
n the  duodenum.  Multiunit  pellet  system  (MUPS)  formula-
ions, since  they  are  soluble  and  contain  a  large  number  of
ndividual microspheres  with  individual  enteric  protection,
llow for  the  use  of  omeprazole  and  esomeprazole  at  any
ge and  through  a  feeding  tube,  as  it  is  possible  to  dilute
he drug.42
Omeprazole  may  be  used  at  doses  ranging  from  0.7  to
.5 mg/kg/day.1,42.43 The  maximum  dose  used  in  children
n published  studies  was  80  mg/day,  based  on  symptoms
r esophageal  pH-monitoring.43 The  pharmacokinetics  of
meprazole and  other  PPIs  is  not  well  established  in  chil-
ren below  1  year  of  age.1,43 Extrapolating  from  adult  data,
t appears  that  PPIs  may  eventually  be  used,  when  necessary,
s symptomatic  drugs.  PPIs  are  widely  used  in  pediatrics,
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although  scientiﬁc  evidence  for  the  use  in  this  age  group  is
limited.44,45
Long-term  PPI  administration  is  not  advisable  without  a
previous investigation.1 In  cases  where  acid  suppression  is
required, the  minimum  possible  dose  should  be  used.  Most
patients require  a  single  daily  dose.  The  routine  use  of
twice daily  dose  is  not  indicated.  Treatment  discontinuation
should be  attempted  whenever  possible,  as  few  patients  will
require long-term  treatments.38,40
Hassall  et  al.,46 in  a  recent  study,  demonstrated  that
62.5% of  patients  with  erosive  esophagitis  who  had  a  relapse
and required  chronic  treatment  with  PPIs  had  a  predisposing
disease, such  as  neurological  alterations  or  esophageal  atre-
sia. Only  33%  of  those  who  had  no  predisposing  conditions
to GERD  required  prolonged  treatment.46
After  prolonged  use,  the  dose  should  be  gradually
reduced. In  some  patients,  abrupt  discontinuation  of  PPI
treatment may  cause  a  rebound  effect  on  acid  produc-
tion, thus  it  is  necessary  to  gradually  wean  the  patient
from the  therapy.1 When  PPIs  are  abruptly  discontinued,
the parietal  cell  mass  that  was  blocked  is  released  from  its
suppression and  acid  hypersecretion  rebound  occurs.47 This
may cause  symptom  exacerbation,  requiring  more  PPIs,47
an  aspect  demonstrated  in  a  study  of  asymptomatic  adults
that received  PPIs  for  three  months  and  developed  gas-
trointestinal symptoms  when  the  medication  was  abruptly
discontinued.48
Use and abuse of acid suppression therapy in
pediatrics
GER  is  a  physiological  process  in  most  infants.  Studies  in  nor-
mal infants  have  demonstrated  reﬂux  episodes  as  often  as
73 times  a  day,49 with  regurgitation  associated  with  reﬂux
episodes in  67%  of  children  in  the  fourth  month  of  life.50 For
the great  majority  of  infants  (98%),  GER  symptoms  improve
up to  12  to  15  months  of  age,  as  the  child  develops,  lower
esophageal sphincter  maturation  occurs,  solid  food  is  intro-
duced, muscle  tone  increases,  and  the  baby  spends  more
time in  the  upright  position.51 In  summary,  GER  symptoms
are more  common  in  young  infants,  with  a  peak  at  4  months
of age,  and  tend  to  disappear  during  the  second  half  of  the
ﬁrst year  of  life.50,52 Differently,  GERD  is  not  frequent  in  this
age group.
The response  of  infants  to  different  stimuli,  including
GER and  GERD,  are  nonspeciﬁc  and  very  similar,  making
it sometimes  difﬁcult  to  establish  the  cause  of  irritabil-
ity or  crying.  Several  studies  have  demonstrated  that  acid
suppression does  not  control  symptoms  such  as  irritability,
crying, and  fussiness,  which  are  interpreted  as  symptoms
of GERD.53,54 There  is  also  some  evidence  that  placebo
improves symptoms  in  infants  as  much  as  PPIs.53,54 In  the
largest double-blind,  randomized,  placebo-controlled  trial
in which  infants  with  GERD  symptoms  received  a  PPI  or
placebo, the  response  was  exactly  the  same  in  both  groups.
In this  study  out  of  the  patients  who  received  placebo,  as
well as  those  who  received  PPI  (lansoprazole)  for  four  weeks,
54% showed  satisfactory  response,  but  the  group  receiving
the active  medication  had  more  side  effects.53 A  smaller
placebo-controlled trial  with  a  different  PPI  showed  very
similar ﬁndings.54
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It  must  not  be  forgotten  that  cultural  factors  affect  feed-
ng practices,  and  studies  have  shown  that  infants  with  GERD
hould be  evaluated  in  terms  of  feeding  behavior  related  to
aternal practices,  problems,  and  beliefs.
Maternal  aspects  that  must  be  evaluated  are  depres-
ion, anxiety,  feeding  problems,  and  impaired  mother--child
nteraction.55,56 Maladaptive  eating  behaviors  should  also
eceive proper  attention.  Interventions  may  be  needed
efore a  negative  reinforcement,  including  tests  and  medi-
ations, is  created.55,56
According  to  some  studies,38,40,57--59 there  is  an  epidemic
f overuse  of  PPIs  in  the  ﬁrst  year  of  life  in  North  America;
his also  appears  to  be  the  case  in  Brazil.  A  study  of  575,000
rescriptions in  the  United  States,  demonstrated  that  the
umber of  gastric  acid-suppressing  medications  prescribed
o children  under  4  years  of  age  increased  56%  between
002 and  2006.60 They  estimated  that  3%  of  all  children  in
his age  group  were  receiving  some  type  of  medication  for
cid suppression.60 The  highest  increase  was  among  infants
elow 1  year  of  age.  Another  North  American  study  observed
n increase  of  more  than  seven-fold  in  PPI  use  between
he years  of  1999  and  2004,  and  the  use  of  a liquid  for-
ulation for  babies  presented  a  16-fold  increase  during  this
eriod.60
Reviewers  of  the  Food  and  Drug  Administration  (FDA)  in
he United  States  published  an  article  in  the  Journal  of  Pedi-
tric Gastroenterology  and  Nutrition61 in  January  of  2012,
eviewing the  studies  commissioned  to  the  pharmaceutical
ndustry on  PPI  use  in  the  ﬁrst  year  of  life.  According  to
hese authors,  the  increase  in  prescriptions  for  PPIs  in  the
rst year  of  life  was  11-fold  between  2002  and  2009.61 They
valuated four  randomized  controlled  trials  and  concluded
hat PPIs  should  not  be  administered  to  treat  symptoms  of
ER in  normal  infants  without  solid  evidence  that  acid  is  the
ause of  the  symptoms.61 This  article  offers  the  following
onclusions:
 Normal  infants  with  symptoms  of  GER  should  be  initially
treated  with  conservative  measures  (dietary  and  postural
guidelines),  and  evaluated  for  CMPA.  Most  of  these  infants
improve  with  time  and  do  not  have  acid-induced  disease,
and  thus  they  do  not  beneﬁt  from  PPIs.  If  conservative
measures  fail,  and  the  investigation  of  another  etiology
is  negative,  the  patient  should  be  referred  to  a  pediatric
gastroenterologist.
 The  use  of  PPIs  should  be  reserved  for  infants  with  docu-
mented  acid-induced  disease,  such  as  erosive  esophagitis.
Without  proven  evidence,  the  balance  between  risks  and
beneﬁts  of  PPIs  is  not  favorable  in  this  age  group,  and  the
long-term  effects  of  their  use  have  not  been  studied.
 Short  and  long-term  safety  studies  are  limited.
 The  diagnostic  tests  available  and  symptoms  are  not  accu-
rate  enough  to  indicate  treatment  with  PPIs  in  infants.
 More  studies  evaluating  PPIs  should  be  performed,  espe-
cially  in  infants  with  erosive  esophagitis,  cystic  ﬁbrosis,
short  bowel,  and  extra-esophageal  manifestations.  In  ero-
sive  esophagitis,  efﬁcacy  can  be  extrapolated  from  other
studies  in  adults  and  children.61Therefore,  the  main  concern  with  GERD  management  is
elated to  infants,  as  presently  there  are  no  studies  that
emonstrate clear  efﬁcacy  of  PPIs  for  the  treatment  of
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Table  2  Studies  with  PPIs  in  pediatric  GERD.
Authors/year  PPI/time  Design  Age/n  Results/observations
Tolia  V  et  al.69 Lansoprazole  15  or  30  mg,  eight  to  12
weeks
Open,  multicentric
Phase  I/II  study
Children aged  1  to  11  years
n =  66
Considered  safe  and  well  tolerated
78%  healed  EE  in  week  eight,  and  100%  in  week  12
AE:  headache,  constipation.
Gremse D  et  al.70 Lansoprazole  15  or  30  mg
Studies  carried  out  ﬁve  days  after
beginning  of  use
Open,  multicentric
Phase  I/II  study
Pharmacokinetics  and  dynamics
Children aged  1  to  11  years
n =  66
Pharmacokinetic  properties  similar  to
adults/lansoprazole  increases  mean  intragastric
pH  in  24  hours  and  the  %  of  time  in  which  pH  is
above 3  or  4
Gunasekaran
et al. 71
Lansoprazole  15  or  30  mg
Studies carried  out  ﬁve  days  after
beginning  of  use
Open,  multicentric  Adolescents  aged  12  to  17
years
Pharmacokinetic  properties  similar  to
adults/lansoprazole  15  mg  or  30  mg  1x/day  used
for ﬁve  days  increases  the  intragastric  pH,
relieves  symptoms,  and  is  well  tolerated
Phase  I/II  study
Pharmacokinetics  and  dynamics  n  =  63
AE:  allergies,  diarrhea,  rash,  dizziness.
Fiedorek S
et al.72
Lansoprazole  15  or  30  mg
eight weeks
Open  Adolescents  aged  12  to  17
years
Lansoprazole 15  and  30  mg  reduced  symptoms  of
adolescents  with  NERD  and  EE,  respectively.  Both
doses  were  considered  safe
Phase I/II  study  n=  64  NERD  (15  mg)
Efﬁcacy and  safety  n=  23  EE  (30  mg)
AE:  headache,  abdominal  pain,  nausea  and
dizziness.
Gold  BD  et  al.73 Esomeprazole
20  and  40  mg
Eight weeks
Multicentric,  randomized,  and
double-blinded non
placebo-controlled
Adolescents aged  12  to  17
years
Esomeprazole  decreased  symptoms  in  both  groups
n =  148  AE:  headache,  8%;  abdominal  pain,  3%;  nausea,
2%;  diarrhea,  2%.  No  severe  AE
Orenstein SR
et al.53
Lansoprazole
four  weeks
Multicentric,  double-blinded,
parallel, placebo-controlled.
Infants aged  1  to  12  months
n =  162
54%  of  response  in  the  two  groups
Tolia V  et  al.74 Esomeprazole  oral  route
5 or  10  mg/day  <  20  kg
10 or  20  mg/day  >  20  kg
0.2 or  1  mg/kg/day
Eight weeks
Multicentric,  randomized,
parallel and  double-blinded
(for dose).
1 to  11  years
n =  109
GERD  conﬁrmed  endoscopically  or  histologically
Healing  of  macro  or  microscopic  erosive
esophagitis
Baker  R  et  al.75 Pantoprazole  delayed  release  oral
suspension
Multicentric,  randomized,  and
double-blinded.
1 to  5  years.
n =  60
GERD  conﬁrmed  endoscopically  or  histologically
0.3; 0.6  and  1.2  mg/kg  Improvement  of  symptoms
Eight  weeks  AE  did  not  increase  with  higher  doses
G
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Table  2  (Continued)
Authors/year  PPI/time  Design  Age/n  Results/observations
Winter  et  al.51 Pantoprazole  delayed-release  oral
granules
Randomized,  double-blinded,
placebo-controlled  (treatment
and withdrawal)
1 to  11  months
n =  106
Patients  with  GERD  symptoms
In blind  phase,  no  differences  between  the
withdrawal  of  pantoprazole  or  placebo  due  to
lack  of  efﬁcacy
1.2 mg/kg/day
Four  weeks  of  pantoprazole  and  four
weeks  double-blind  pantoprazole  x
placebo
Safe  and  well  tolerated
Tammara  BK
et al.76
Pantoprazole
0.6  mg/kg
1.2  mg/lg
Multicentric,  open,
randomized.
Pharmacokinetics
Study 1  -- 1  month  to  12
months
n =  43
Exposure  increases  with  increasing  dose,  but
there  is  great  individual  variation.
Study 1 Oral  granules Study  2  -- 1 year  to  <  6  years Exposure  was  similar  to  adults.
Study 2 Measurements  performed  at  least
after  ﬁve  consecutive  doses
n =  17 Well  tolerated.
Ward  RM  et  al.77 Delayed-release  pantoprazole  tablets Multicentric,  open,
randomized.
6 to  16  years. Patients  with  GERD  have  the  same  systemic
exposure  of  adults.
20  or  40  mg/day n  =  38 No  serious  adverse  effects.
Measurements  performed  12  hours
after a  single  dose  and  two  to  four
hours after  multiple  doses
Pharmacokinetics  and  safety
Sandström  M
et al.78
Esomeprazole  IV  1x/day
Four days
Multicentric,  open,
randomized, Phase  I
0  to  17  years. Clearance  increases  with  weight  and  age.
Well  tolerated
31 patients  with  AE
Pharmacokinetics  and
tolerability IV
n =  57 No  severe  AE
Kukulka  M  et  al.79 MR  dexlansoprazole
30 or  60  mg  for  seven  days
Multicentric,  parallel,  open,
Phase I
Pharmacokinetics  and  safety
2  to  17  years.
n =  36
Pharmacokinetics  similar  to  adults
Mild adverse  effects  (33.3%)
Winter H  et  al.80 Esomeprazole
2.5  to  10  mg/day
Four weeks
Multicentric,  randomized,
double-blinded,
placebo-controlled  (treatment
and withdrawal)
1 to  11  months
n =  98
There  was  no  statistical  difference  in  treatment
interruption  due  to  worsening  of  symptoms
between  esomeprazole  and  placebo
Hassall et  al.46 Omeprazole
0.7  to  3.5  mg/kg/day
21 months
Prospective,  open,  long-term
to test  maintenance  dose.
1  to  16  years  with  healed  EE
n= 32  (completed  the  study)
Remission was  achieved  with  continuous  use  of
omeprazole  in  most  patients.
60% required  more  than  half  of  the  dose  required
for  healing
AE, adverse effect, EE, erosive esophagitis; GERD, gastroesophageal reﬂux disease; LRTI, lower respiratory tract infection; NERD, non-erosive reﬂux disease; PPIs, proton pump inhibitors.
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onspeciﬁc  manifestations  as  crying  and  irritability.55,59 This
xaggeration regarding  the  treatment  of  GERD  in  infants
oes not  occur  without  potential  adverse  effects  docu-
ented in  the  literature.  Gastric  acid  is  important  for
rotection against  infections  and  for  the  absorption  of  cer-
ain nutrients.38
Currently,  there  are  very  few  randomized  controlled
rials providing  support  for  the  use  of  medications  to
reat symptoms  consistent  with  GERD  in  the  ﬁrst  year  of
ife.62 However,  a  study  with  1,245  American  pediatricians
bserved that  82%  of  the  respondents  agreed  that  they  would
tart empirical  acid  suppression  before  ordering  diagnostic
ests.63
In  this  context,  the  possible  beneﬁts  of  a non-
harmacological  conservative  treatment,  with  changes  in
iet and  lifestyle,  are  important  in  order  to  not  expose
nfants to  unnecessary  medications  and  to  prevent  adverse
ffects and  costs.64 Shalaby  et  al.65 conducted  a  study  in
hich a  nurse,  experienced  in  GER/GERD  guidelines,  advised
arents of  infants  with  suspected  symptoms  of  GERD  by  tele-
hone on  conservative  measures.  These  recommendations
educed symptoms  in  26%  of  infants,  thus  avoiding  the  need
or consultation  with  the  gastroenterologist.65 Patients  were
nstructed  to  use  thickened  and/or  extensively  hydrolyzed
ormula, or  the  mother  was  instructed  to  follow  a CM  and
oy elimination  diet,  to  avoid  exposure  to  smoke,  and  to  fol-
ow  the  position  guidelines.  After  two  weeks,  78%  of  patients
mproved, of  whom  59%  presented  a  decrease  in  at  least  ﬁve
tems of  the  symptom  questionnaire,  and  24%  remained  free
f symptoms.65
inal considerations
nfants  have  nonspeciﬁc  responses  to  different  patho-
ogical and  non-pathological  stimuli:  crying,  irritability,
efusal to  eat,  sleep  disorders,  back  arching,  and  appar-
nt discomfort.66 Pediatricians  have  less  time  to  listen
o parents  and  caregivers,  rather  than  taking  a  com-
lete history  that  includes  behavioral  and  dietary  details
nd reassuring  them.  Furthermore  there  is  an  additional
ressure to  ‘‘solve  the  problem’’  and  ‘‘do  something’’
hich leads  the  pediatrician  to  choose  the  fast  track:  to
rescribe!
It appears  to  be  less  risky,  but  it  brings  consequences  for
he patients,  as  it  is  less  expensive  to  try  a  more  conservative
pproach rather  than  prescribing  several  medications.67,68
n  the  light  of  current  knowledge,  it  would  be  better  to
dvise patients  and  their  caregivers  and  to  prescribe  fewer
edications.
In patients  with  persistent  symptoms,  referral  to  a  pedi-
tric gastroenterologist  is  advised  in  order  to  assess  the  need
f diagnostic  investigations,  and  proper  pharmacological  or
ossible surgical  treatment.  Studies  on  PPI  use  in  children
re presented  in  Table  2.46,51,53,69--80
onﬂicts of interestll  authors  have  received  honoraria  for  educational  activ-
ties organized  by  Support,  Abbott,  Danone,  and  Nestlé
utrition.
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